1. Home
  2. EQX vs NVAX Comparison

EQX vs NVAX Comparison

Compare EQX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equinox Gold Corp.

EQX

Equinox Gold Corp.

HOLD

Current Price

$10.51

Market Cap

10.9B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.85

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQX
NVAX
Founded
2007
1987
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
1.5B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
EQX
NVAX
Price
$10.51
$8.85
Analyst Decision
Buy
Hold
Analyst Count
1
9
Target Price
$17.00
$11.33
AVG Volume (30 Days)
11.4M
4.7M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
0.11%
N/A
EPS Growth
N/A
309.76
EPS
N/A
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
$102.84
N/A
Revenue Next Year
$15.55
N/A
P/E Ratio
$137.41
N/A
Revenue Growth
N/A
64.69
52 Week Low
$5.64
$6.20
52 Week High
$18.96
$11.85

Technical Indicators

Market Signals
Indicator
EQX
NVAX
Relative Strength Index (RSI) 36.70 44.55
Support Level $10.28 $7.75
Resistance Level $11.11 $9.02
Average True Range (ATR) 0.63 0.71
MACD -0.15 -0.20
Stochastic Oscillator 23.22 14.72

Price Performance

Historical Comparison
EQX
NVAX

About EQX Equinox Gold Corp.

Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: